- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.
Objectives:
- Review the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)
- List the currently available treatment recommendations and guidelines for AAD treatment recommendations
- Identify gaps with current treatment options, both pharmacologic and nonpharmacologic
Featuring
W. Clay Jackson, MD, DipTh
Assistant Professor of Clinical Psychiatry & Family Medicine; University of TN College of Medicine
Bryan Archuleta, PharmD (OPDC)
Senior Long-Term Care Medical Science Liaison
Speaker W. Clay Jackson, MD, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Bryan Archuleta, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
-
Monoamine Neurotransmitter Dysregulation in Major Depressive Disorder
December 17 12:00 pm to 1:00 pm -
Identification of Agitation in Patients with Dementia due to Alzheimer’s Disease: Perspectives from the Primary Care Provider
December 18 12:00 pm to 1:00 pm
Registration
Related Resources
-
Neuroprogression: Understanding How Mental Health Conditions Can Progress Over Time
Infographic November 14, 2024This infographic aims to educate patients and caregivers on the importance of early diagnosis and treatment of mental health conditions and to emphasize how delays in diagnosis and treatment can…
-
Introduction to PTSD
Infographic November 11, 2024This infographic aims to raise awareness of PTSD in a straightforward manner appropriate for both individuals with lived experience, and health care providers.
-
Factors in Designing & Evaluating Clinical Trials for App-Based Interventions
On-Demand Webinar November 4, 2024In this webinar, Dr. Sara Morimoto, PsyD will share her expertise in developing and testing app-based mental health interventions.
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: